Nov 15 (Reuters) - The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, the regulator said. (Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.835 USD | -1.53% | +18.33% | +29.65% |
Jul. 03 | CorMedix Begins Outpatient Distribution of DefenCath | MT |
May. 28 | CorMedix Shares Rise on Multiyear DefenCath Supply Deal | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.65% | 270M | |
+7.39% | 72.48B | |
+31.10% | 10.32B | |
+28.34% | 4.82B | |
-20.02% | 4.59B | |
+18.94% | 3.72B | |
+24.92% | 2.21B | |
-36.80% | 1.88B | |
-43.31% | 1.8B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- U.S. FDA approves CorMedix's antimicrobial drug